Pioglitazone prevents corporal veno‐occlusive dysfunction in a rat model of type 2 diabetes mellitus
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To determine whether corporal veno‐occlusive dysfunction (CVOD), corporal smooth muscle (SM) loss, fibrosis and oxidative stress occur in a rat model of type 2 diabetes, and whether these are counteracted by pioglitazone, as pioglitazone is vasculoprotective, and corporal SM is an extension of arterial SM. MATERIALS AND METHODS: Male obese Zucker fa/fa rats were fed chow containing 0%, 0.001% or 0.02% pioglitazone for 2 or 5 months, using untreated lean Zucker and Fischer 344 rats as controls. Functional changes were determined by dynamic‐infusion cavernosometry. Histological changes were assessed by histochemistry and immunohistochemistry followed by quantitative image analysis and/or quantitative Western blot. RESULTS: CVOD was detected at 4.5 months of diabetes, accompanied by a lower corporal SM/collagen ratio, and increases in collagen, collagen III/I ratio, apoptotic index, and systemic and tissue oxidative stress. In the short‐term treatment, high‐dose pioglitazone normalized glycaemia and ameliorated fibrosis and oxidative stress, but induced CVOD, whereas the effects with the low dose were not significant. However, low‐dose pioglitazone for 5 months corrected all alterations. CONCLUSION: Type 2 diabetes in Zucker fa/fa rats was associated with penile corporal fibrosis, oxidative stress, and CVOD, which were ameliorated by long‐term low‐dose pioglitazone, suggesting that this drug might protect the SM, independently from its antidiabetic effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie's disease
Gonzalez-Cadavid, N. F., & Rajfer, J. (2005) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0201 · Cited by 168
Self-citationDavila, H. H., Magee, T. R., Vernet, D., Rajfer, J., & Gonzalez-Cadavid, N. F. (2004) · Biology of Reproduction · doi:10.1095/biolreprod.104.030833 · Cited by 91
Self-citationCardiovascular Risk Factors Associated with Insulin Resistance: Effects of Oral Antidiabetic Agents
Granberry, M. C., & Fonseca, V. A. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505030-00006 · Cited by 38
Cited by
Anatomy, Physiology, and Pathophysiology of Erectile Dysfunction
Gratzke, C., Angulo, J., Chitaley, K., Dai, Y.-T., Kim, N. N., Paick, J.-S., Simonsen, U., Ückert, S., Wespes, E., Andersson, K. E., et al. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01624.x · Cited by 464
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., Faggiano, A., Pozzilli, P., Isidori, A. M., & Gianfrilli, D. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3494 · Cited by 285
The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance
Traish, A. M., Saad, F., & Guay, A. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.005751 · Cited by 266
Gonzalez-Cadavid, N. F. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.01195.x · Cited by 172
Ferrini, M. G., Rivera, S., Moon, J., Vernet, D., Rajfer, J., & Gonzalez-Cadavid, N. F. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01884.x · Cited by 60
Self-citation
Metadata
- Authors
- KOVANECZ, I., FERRINI, M. G., VERNET, D., NOLAZCO, G., RAJFER, J., & GONZALEZ‐CADAVID, N. F.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2006-06-08
- Volume
- 98
- Issue
- 1
- Pages
- 116-124
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W2075686284
- Cited by
- 81
- References
- 3
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pioglitazone prevents corporal veno‐occlusive dysfunction in a rat model of type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/j.1464-410x.2006.06268.x
- The paper
- KOVANECZ, I., FERRINI, M. G., VERNET, D., NOLAZCO, G., RAJFER, J., & GONZALEZ‐CADAVID, N. F. (2006). Pioglitazone prevents corporal veno‐occlusive dysfunction in a rat model of type 2 diabetes mellitus. BJU International. https://doi.org/10.1111/j.1464-410x.2006.06268.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.